2.2. Trial Design
This was an open-label, single-arm, single-center, exploratory phase II study. The protocol was approved by the Ministry of Food and Drug Administration of Korea (approval no. 32764) and by the investigational review board of Soonchunhyang University Hospital. Patients gave written consent after being informed about the characteristics of the clinical trial and the investigational drug.